Back to Authors

Lapid, Maria I.

0000-0002-1163-5584

Mayo Clinic

Mayo Clinic

Citations 107

Prominent Auditory Hallucinations in Behavioral Variant Frontotemporal Dementia Associated with a MAPT Mutation (P3.1-006)
Widmeyer, Mary, Gavrilova, Ralitza, Fields, Julie A. , Forsberg, Leah K. , Lowe, Val J. , Lapid, Maria I. , Kantarci, Kejal , Boeve, Bradley F.

Neurology | December 7, 2023 | Volume: 92 | Issue: 15_supplement | Pages: No page available

10.1212/wnl.92.15_supplement.p3.1-006 Get It

Impact of Armodafinil Therapy on Neuropsychiatric Features in Dementia with Lewy Bodies (S1.004)
Kuntz, Karen M. , Mason, Sara S., Aakre, Jeremiah A. , Boeve, Bradley, Lapid, Maria I. , Lundt, Emily S.

Neurology | December 7, 2023 | Volume: 86 | Issue: 16_supplement | Pages: No page available

10.1212/wnl.86.16_supplement.s1.004 Get It

Impact of Armodafinil Therapy on Neuropsychiatric Features in Dementia with Lewy Bodies (I9.003)
Kuntz, Karen M. , Mason, Sara S., Aakre, Jeremiah A. , Lapid, Maria I. , Lundt, Emily S. , Boeve, Bradley F.

Neurology | December 7, 2023 | Volume: 86 | Issue: 16_supplement | Pages: No page available

10.1212/wnl.86.16_supplement.i9.003 Get It

A Novel Approach to Monitoring Cognitive Adverse Events for Interventional Studies Involving Advanced Dementia Patients: Insights From the Electroconvulsive Therapy for Agitation in Dementia Study
Park, Soohyun , Forester, Brent P. , Harper, David G. , Hermida, Adriana P., Inouye, Sharon K. , McClintock, Shawn M. , Nykamp, Louis, Petrides, Georgios, Schmitt, Eva M., Seiner, Stephen J., Patrick, Regan , Lapid, Maria I. , Mueller, Martina

Journal of Geriatric Psychiatry and Neurology | October 17, 2023 | Volume: 37 | Issue: 3 | Pages: 234-241

10.1177/08919887231207641 Get It

Objective To develop an individualized method for detecting cognitive adverse events (CAEs) in the context of an ongoing trial of electroconvulsive therapy for refractory agitation and aggression for advanced dementia (ECT-AD study). Methods Literature search aimed at identifying (a) cognitive measures appropriate for patients with advanced dementia, (b) functional scales to use as a proxy for cognitive status in patients with floor effects on baseline cognitive testing, and (c) statistical approaches for defining a CAE, to develop CAEs monitoring plan specifically for the ECT-AD study. Results Using the Severe Impairment Battery-8 (SIB-8), baseline floor effects are defined as a score of ≤5/16. For patients without floor effects, a decline of ≥6 points is considered a CAE. For patients with floor effects, a decline of ≥30 points from baseline on the Barthel Index is considered a CAE. These values were derived using the standard deviation index (SDI) approach to measuring reliable change. Conclusions The proposed plan accounts for practical and statistical challenges in detecting CAEs in patients with advanced dementia. While this protocol was developed in the context of the ECT-AD study, the general approach can potentially be applied to other interventional neuropsychiatric studies that carry the risk of CAEs in patients with advanced dementia.
Understanding paradoxical lucidity: Family caregiver interpretations of lucid episodes among people with late‐stage Alzheimer’s disease and related dementias
Finnie, Dawn, Biggar, Virginia , Frangiosa, Theresa, Griffin, Joan M. , Finnie, Dawn M., Kim, Kyungmin , Lapid, Maria I. , Gaugler, Joseph E.

Alzheimer's & Dementia | June 16, 2023 | Volume: 19 | Issue: S5 | Pages: No page available

10.1002/alz.068192 Get It

AbstractBackgroundParadoxical lucidity is characterized by spontaneous mental clarity with verbal or non‐verbal communication or behavior among people with AD who had previously been thought to lack the cognitive capacity to do so. With a paucity of data available, family caregivers (FCGs) provide critical perspectives on characteristics of these episodes of lucidity (EL).MethodTwenty‐four FCGs who witnessed at least one EL were interviewed about the experience. Qualitative data were transcribed, double coded, and analyzed to help characterize ELs.ResultFCGs described ELs as indelible moments, possibly triggered by music, food, holidays, or impending death. The spontaneity of the EL, its duration, the connectedness with FCGs, and coherence of communication varied. Instead of seeing them as cognitive fluctuations, FCGs often assigned metaphysical meaning to ELs.ConclusionFCG descriptions of ELs had few common patterns, suggestions they are heterogenous. Their impact on FCGs, however, was enduring.
Neuropsychiatric symptom progression in predementia frontotemporal dementia mutation carriers
Lee, Hyunwoo , Chatterjee, Atri , Mackenzie, Ian R. , Huey, Edward D. , Wittenberg, Dana, Rosen, Howard J. , Boxer, Adam L. , Rankin, Katherine P. , Lapid, Maria I. , Boeve, Bradley F. , Hsiung, Ging‐Yuek Robin

Alzheimer's & Dementia | June 16, 2023 | Volume: 19 | Issue: S4 | Pages: No page available

10.1002/alz.068081 Get It

AbstractBackgroundNeuropsychiatric symptoms (NPS) often occur during the prodromal stage of frontotemporal dementia (FTD), as evidenced by the presence of early psychiatric diagnosis in approximately 50% of bvFTD patients prior to their dementia diagnosis. We hypothesized that carriers of mutations in progranulin (GRN+), chromosome 9 open reading frame 72 (C9orf72+) and microtubule associated protein tau (MAPT+) have increased baseline burden and rates of progression of NPS compared to non‐carrier individuals prior to onset of dementia symptoms based on the Clinical Dementia Rating (CDR) scale.MethodParticipants were recruited through the ARTFL‐LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD) Study. NPS were assessed with Neuropsychiatric Inventory‐Questionnaire (NPI‐Q), Geriatric Depression Scale (GDS), Interpersonal Reactivity Index (IRI), Social Behaviour Checklist (SBOCL), and Behavioral Inhibition Scale (BIS) annually for up to five years. We selected participants with CDR scores of 0 and 0.5. If a participant’s CDR changed to above 0.5 during the follow‐up, we only analyzed observations collected before the conversion. We used mixed effects models to compare the baseline burden and the longitudinal progression of NPS measures between carriers and controls, adjusted for baseline age, sex, education, and baseline Montreal Cognitive Assessment (MoCA) scores.ResultWe analyzed data from 607 participants (111 C9orf72+, 47 GRN+, 67 MAPT+ and 382 non‐carrier controls). There were no significant group differences in baseline demographic features, except that MAPT+ was significantly younger than other groups (average age: C9orf72+ = 45, GRN+ = 53, MAPT+ = 41, controls = 54). Baseline NPS scores were not significantly different between carriers and controls, except that C9orf72+ had significantly lower GDS compared to controls (p = 0.002). Longitudinally, GRN+ (p = 0.02) and MAPT+ (p = 0.009) had significantly higher rates of NPI‐Q increases compared to controls, while the progression of NPI‐Q in C9orf72+ was comparable to controls. The rates of GDS, IRI, SBOCL and BIS progression were not significantly different between carriers and controls.ConclusionPrior to the onset of dementia, GRN+ and MAPT+ have a faster progression of NPS, as measured by NPI‐Q, compared to controls. Future work will investigate whether different mutation carriers are affected by specific type/cluster of symptoms.
Feasibility and acceptability of remote smartphone cognitive testing in frontotemporal dementia research
Taylor, Jack C. , Heuer, Hilary W. , Clark, Annie L , Wise, Amy B. , Manoochehri, Masood , Forsberg, Leah K. , Mester, Carly , Rao, Meghana , Brushaber, Daniell, Kramer, Joel H. , Welch, Ariane E., Kornak, John , Kremers, Walter K. , Domoto‐Reilly, Kimiko , Fields, Julie A. , Ghoshal, Nupur , Graff‐Radford, Neill R. , Hall, Matthew , Huey, Edward D. , Mackenzie, Ian R. , Masdeu, Joseph C. , Mendez, Mario F. , Onyike, Chiadi U. , Pascual, Belén , Pressman, Peter , Rankin, Katherine P. , Ratnasiri, Buddhika , Wong, Bonnie , Gorno‐Tempini, Maria Luisa , Rosen, Howard J. , Boxer, Adam L. , Staffaroni, Adam M. , Taylor, Jack Carson , Staffaroni, Adam M , Pascual, Belen , Kremers, Walter K , Domoto-Reilly, Kimiko , Brushaber, Danielle , Appleby, Brian S. , Dickerson, Bradford Clark , Grossman, Murray , Irwin, David J. , Lapid, Maria I. , Litvan, Irene , Masdeu, Joseph C , Nevler, Naomi , Rojas, Julio C. , Tartaglia, Maria Carmela , Boeve, Bradley F.

Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring | May 10, 2023 | Volume: 15 | Issue: 2 | Pages: No page available

10.1002/dad2.12423 Get It

AbstractIntroductionRemote smartphone assessments of cognition, speech/language, and motor functioning in frontotemporal dementia (FTD) could enable decentralized clinical trials and improve access to research. We studied the feasibility and acceptability of remote smartphone data collection in FTD research using the ALLFTD Mobile App (ALLFTD‐mApp).MethodsA diagnostically mixed sample of 214 participants with FTD or from familial FTD kindreds (asymptomatic: CDR®+NACC‐FTLD = 0 [N = 101]; prodromal: 0.5 [N = 49]; symptomatic ≥1 [N = 51]; not measured [N = 13]) were asked to complete ALLFTD‐mApp tests on their smartphone three times within 12 days. They completed smartphone familiarity and participation experience surveys.ResultsIt was feasible for participants to complete the ALLFTD‐mApp on their own smartphones. Participants reported high smartphone familiarity, completed ∼ 70% of tasks, and considered the time commitment acceptable (98% of respondents). Greater disease severity was associated with poorer performance across several tests.DiscussionThese findings suggest that the ALLFTD‐mApp study protocol is feasible and acceptable for remote FTD research.HIGHLIGHTS The ALLFTD Mobile App is a smartphone‐based platform for remote, self‐administered data collection. The ALLFTD Mobile App consists of a comprehensive battery of surveys and tests of executive functioning, memory, speech and language, and motor abilities. Remote digital data collection using the ALLFTD Mobile App was feasible in a multicenter research consortium that studies FTD. Data was collected in healthy controls and participants with a range of diagnoses, particularly FTD spectrum disorders. Remote digital data collection was well accepted by participants with a variety of diagnoses.
Semantic Variant Primary Progressive Aphasia Associated with the C9orf72 Hexanucleotide Expansion – A Longitudinal Case Report (P13-6.004)
Switzer, Aaron , Fields, Julie A. , Kantarci, Kejal , Lowe, Val J. , Gavrilova, Ralitza H. , Forsberg, Leah K. , Nelson, Kevin L., Kolander, Tyler, Kantarci, Kejal , Switzer, Aaron R , Corriveau‐Lecavalier, Nick , Jones, David T. , Botha, Hugo , Knopman, David S. , Ramanan, Vijay K. , Lapid, Maria I. , Nelson, Kevin, Boeve, Bradley F.

Neurology | April 28, 2023 | Volume: 100 | Issue: 17_supplement_2 | Pages: No page available

10.1212/wnl.0000000000203291 Get It

Multisite ALLFTD study modeling progressive empathy loss from the earliest stages of behavioral variant frontotemporal dementia
Toller, Gianina , Callahan, Patrick , Brushaber, Danielle , Domoto‐Reilly, Kimiko , Forsberg, Leah K. , Ghoshal, Nupur , Graff‐Radford, Jonathan, Graff-Radford, N. R., Heuer, Hilary W. , Kornak, John , Kremers, Walter K. , Mackenzie, Ian R. , Pascual, María Belén, Ramos, Eliana Marisa , Rascovsky, Katya, Staffaroni, Adam M. , Tartaglia, Maria Carmela , Weıntraub, Sandra , Boxer, Adam L. , Rosen, Howard J. , Rankin, Katherine P. , Graff-Radford, Neil R, Boeve, Brad F, Tartaglia, Maria Carmela , Kremers, Walter K , Domoto-Reilly, Kimiko , Cobigo, Yann , Appleby, Brian S. , Graff‐Radford, Jonathan , Grossman, Murray , Lapid, Maria I. , Léger, Gabriel C. , Litvan, Irene , Rojas, Julio C. , Toga, Arthur W. , Wszołek, Zbigniew K. , Boeve, Bradley F.

Alzheimer's & Dementia | January 2, 2023 | Volume: 19 | Issue: 7 | Pages: 2842-2852

10.1002/alz.12898 Get It

AbstractIntroductionEmpathy relies on fronto‐cingular and temporal networks that are selectively vulnerable in behavioral variant frontotemporal dementia (bvFTD). This study modeled when in the disease process empathy changes begin, and how they progress.MethodsFour hundred thirty‐one individuals with asymptomatic genetic FTD (n = 114), genetic and sporadic bvFTD (n = 317), and 163 asymptomatic non‐carrier controls were enrolled. In sub‐samples, we investigated empathy measured by the informant‐based Interpersonal Reactivity Index (IRI) at each disease stage and over time (n = 91), and its correspondence to underlying atrophy (n = 51).ResultsEmpathic concern (estimate = 4.38, 95% confidence interval [CI] = 2.79, 5.97; p < 0.001) and perspective taking (estimate = 5.64, 95% CI = 3.81, 7.48; p < 0.001) scores declined between the asymptomatic and very mild symptomatic stages regardless of pathogenic variant status. More rapid loss of empathy corresponded with subcortical atrophy.DiscussionLoss of empathy is an early and progressive symptom of bvFTD that is measurable by IRI informant ratings and can be used to monitor behavior in neuropsychiatry practice and treatment trials.